HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) was the target of a large drop in short interest during the month of September. As of September 30th, there was short interest totalling 1,400,000 shares, a drop of 28.2% from the September 15th total of 1,950,000 shares. Based on an average daily volume of 3,700,000 shares, the short-interest ratio is currently 0.4 days.
Several analysts have issued reports on the company. HC Wainwright restated a “buy” rating and issued a $1.00 price objective on shares of HTG Molecular Diagnostics in a research note on Wednesday, August 5th. Zacks Investment Research cut HTG Molecular Diagnostics from a “hold” rating to a “sell” rating in a research report on Tuesday, August 18th. Finally, ValuEngine downgraded HTG Molecular Diagnostics from a “buy” rating to a “hold” rating in a research note on Thursday, October 1st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company’s stock. HTG Molecular Diagnostics presently has a consensus rating of “Hold” and an average price target of $0.93.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Cowen Prime Services LLC increased its position in HTG Molecular Diagnostics by 2.8% in the 2nd quarter. Cowen Prime Services LLC now owns 4,579,500 shares of the medical research company’s stock valued at $3,297,000 after acquiring an additional 124,000 shares during the period. BlackRock Inc. increased its position in HTG Molecular Diagnostics by 15.3% in the 1st quarter. BlackRock Inc. now owns 467,900 shares of the medical research company’s stock valued at $152,000 after acquiring an additional 62,175 shares during the period. WINTON GROUP Ltd increased its position in HTG Molecular Diagnostics by 211.7% in the 2nd quarter. WINTON GROUP Ltd now owns 210,815 shares of the medical research company’s stock valued at $152,000 after acquiring an additional 143,172 shares during the period. Squarepoint Ops LLC acquired a new position in HTG Molecular Diagnostics in the 1st quarter valued at approximately $31,000. Finally, UBS Group AG increased its position in HTG Molecular Diagnostics by 172.4% in the 2nd quarter. UBS Group AG now owns 38,308 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 24,247 shares during the period. Hedge funds and other institutional investors own 22.95% of the company’s stock.
NASDAQ:HTGM traded up $0.01 on Friday, hitting $0.33. The company had a trading volume of 724,994 shares, compared to its average volume of 3,077,490. The stock has a market capitalization of $23.04 million, a price-to-earnings ratio of -0.99 and a beta of 1.42. The company has a current ratio of 7.43, a quick ratio of 7.14 and a debt-to-equity ratio of 0.57. The firm has a 50 day moving average of $0.33 and a two-hundred day moving average of $0.48. HTG Molecular Diagnostics has a 52 week low of $0.27 and a 52 week high of $0.99.
HTG Molecular Diagnostics (NASDAQ:HTGM) last issued its quarterly earnings data on Tuesday, August 11th. The medical research company reported ($0.08) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.08). HTG Molecular Diagnostics had a negative net margin of 141.02% and a negative return on equity of 85.82%. The business had revenue of $1.96 million during the quarter, compared to the consensus estimate of $1.90 million. As a group, equities analysts forecast that HTG Molecular Diagnostics will post -0.32 EPS for the current year.
HTG Molecular Diagnostics Company Profile
HTG Molecular Diagnostics, Inc a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation; consumables comprising assay kits; and software that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing.
Recommended Story: How Investors Use a Balance Sheet
Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.